BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
BeyondSpring announced FDA Fast Track designation for Plinabulin combined with docetaxel to treat advanced non-squamous NSCLC patients post immune checkpoint inhibitors and chemotherapy. The company also entered a strategic transaction selling its majority stake in its Chinese subsidiary to an investor who will fund about half of the global Phase 3…